UBS analyst Douglas Schenkel assumes coverage on Myriad Genetics (NASDAQ: MYGN) with a Neutral rating and a price target of $3.60.

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $3.18 yesterday.